Galena Biopharma, Inc. Message Board
-
Only $14M cash but $89M needed for P3
How
GALE will get $89M cash for P3?
Any rational response?-
Have you ever thought that with this new patent protection of NeuVax, GALE will have no problem raising a lot more money to undertake its Phase 3 trials of NeuVax until the FDA grant the approval?
In fact, I think a lot of financial institutions are now chasing GALE to offer them money.- 1 Reply to stockwatcher888
-
sorry raising money is what STOCK is for
institutions buy results, retail buys promise
-
They will get the cash with the toxic financing that is coming. It's on the way. BEND OVER!
-
merge with cldx they have $90 mm and no debt. start to create a powerhouse in the space and avoid selling too early too cheap to big pharma.
- 1 Reply to nickdidomenico
-
Roche is also contributing to the study fyi
-
Who said it requires 89m to do the final? I think Roche will step in. I expect to see a 13D filing soon by them.Remember this news release: Galena Biopharma Announces Clinical Development Collaboration With Genentech/Roche and The Henry M. Jackson Foundation for the ...
-
No debt
-
sleep with 4.5 million fat women for $20 each
-
Sell 10m shares at $10 after 3p results in june.
-
89 million is chump change based upon a potential 15 billion dollar market. Duh!
-
If they have a promising product, they should have no difficulties finding partners or investors.
Roche can be knocking on their door anytime soon for a flat buyout if they have products that can potentially capture what Herceptin can't do- 1 Reply to marubadbad
-
Big pharma 's will be lining up to lend little Galena a hand.
Potential goliath drug here.
-